UNITED
STATES
SECURITIES
AND EXCHANGE COMMISSION
Washington,
D.C. 20549
FORM
6-K
REPORT
OF FOREIGN PRIVATE ISSUER
Pursuant
to Rule 13a-16 or 15d-16
Under
the Securities Exchange Act of 1934
For the
month of February 2009
Commission
File Number: 0-29350
Vasogen
Inc.
(Translation
of registrant’s name into English)
4
Robert Speck Parkway, 15
th
Floor,
Mississauga, Ontario, L4Z 1S1
(Address
of principal executive offices)
Indicate
by check mark whether the registrant files or will file annual reports under
cover of Form 20-F or Form 40-F.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(1). _____
Note:
Regulation S-T Rule 101(b)(1) only permits the submission in paper of a Form 6-K
if submitted solely to provide an attached annual report to security
holders.
Indicate
by check mark if the registrant is submitting the Form 6-K in paper as permitted
by Regulation S-T Rule 101(b)(7): _____
Note:
Regulation S-T Rule 101(b)(7) only permits the submission in paper of a Form 6-K
if submitted to furnish a report or other document that the registrant foreign
private issuer must furnish and make public under the laws of the jurisdiction
in which the registrant is incorporated, domiciled or legally organized (the
registrant's "home country"), or under the rules of the home country exchange on
which the registrant's securities are traded, as long as the report or other
document is not a press release, is not required to be and has not been
distributed to the registrant's security holders, and, if discussing a material
event, has already been the subject of a Form 6-K submission or other Commission
filing on EDGAR.
Indicate
by check mark whether the registrant by furnishing the information contained in
this Form is also thereby furnishing the information to the Commission pursuant
to Rule 12g3-2(b) under the Securities Exchange Act of 1934.
If
“Yes” is marked, indicate below the file number assigned to the registrant in
connection with Rule 12g3-2(b): 82-
.
The
Consolidated Financial Statements and Notes to Consolidated Financial Statements
for the year ended November 30, 2008, together with Report of Independent
Registered Public Accounting Firm thereon, are attached hereto as Exhibit 99.1
and incorporated by reference into this report, the Management’s Responsibility
for Consolidated Financial Statements are attached hereto as Exhibit 99.2 and
incorporated by reference into this report, and the Management's Discussion and
Analysis for the year ended November 30, 2008, are attached hereto as Exhibit
99.3 and incorporated by reference into this report.
SIGNATURE
Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has
duly caused this report to be signed on its behalf by the undersigned, thereunto
duly authorized.
|
|
VASOGEN
INC.
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
By:
|
/s/
Graham Neil
|
|
|
Name:
|
Graham
Neil
|
|
|
Title:
|
Vice-President,
Finance and
|
|
|
|
Chief
Financial Officer
|
Date: February
27, 2009
EXHIBIT
LIST
|
Exhibit
|
|
Description
|
|
|
|
|
|
99.1
|
|
Consolidated
Financial Statements and Notes to Consolidated Financial Statements for
the year ended November 30, 2008, together with Report of Independent
Registered Public Accounting Firm thereon
|
|
99.2
|
|
Management's
Responsibility for Consolidated Financial Statements
|
|
99.3
|
|
Management's
Discussion and Analysis for the period ended November 30,
2009
|
